Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

NCT03472326 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped GS-9131 did not meet the targeted antiviral response

Conditions

HIV-1-infection

Interventions

DRUG: GS-9131
DRUG: BIC
DRUG: TAF
DRUG: ARV regimen
DRUG: DRV
DRUG: RTV

Sponsor

Gilead Sciences